[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@AscendingBio Avatar @AscendingBio AscendingBio

AscendingBio posts on X about $ocul, $mreo, $rare, $aqst the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence cryptocurrencies X%

Social topic influence $ocul 3%, $mreo #2, $rare #20, $aqst #3, med 1%, $kura 1%, $capr 1%, $dcth X%

Top accounts mentioned or mentioned by @smallcapking2 @refinedtrader1 @kaali67800508 @henry431171040 @hkd_tweets @moneyfacturers @hkdtweets @paulallenview @nalyticsatwork @marketmacher @mrdizle @livingnyc212 @rushing9000 @dashwend @barry3252181 @jfais20 @adamexcellent @dubk1 @smilefixr888 @give100percent

Top assets mentioned SuperRare (RARE)

Top Social Posts #

Top posts by engagements in the last XX hours

"$MREO $RARE Data Timing In presentation today it was stated that SETRUSUMAB results will be available in December or January. (Some have been saying December was the latest. I have been asserting January was possible due to past pattern of time required to analyze data.)"
X Link @AscendingBio 2025-10-14T18:14Z XXX followers, 1204 engagements

"$OCUL What Is This Offering About They only imply this but the $XXX million offering is centered around Diabetic Retinopathy. They decided that it makes sense to jump in with both feet. Given how well the study design negotiations went with the FDA they determined that a bold move was the right one. They also have the opportunity to take advantage of using the SOL-1 and SOL-R treatment sites while those relationships are still strong. So it is full speed ahead. The opening that currently exists for Diabetic Retinopathy where patients receive treatments that last for X to XX months is huge."
X Link @AscendingBio 2025-10-01T18:19Z XXX followers, 1389 engagements

"$AQST Belhavan is developing a epinephrine powder that you spray in your nose. This sounds really unpleasant They posted a study in which all XX subjects experienced side effects. Only X made it through the study. They indicated that XXXX% had nasal discomfort XX% had headaches and XXXX% had a reaction where their eyes watered and XX% had nose bleeds. Nothing like a med that hurts your nose gives you a headache makes you cry and gives you a bloody nose"
X Link @AscendingBio 2025-10-10T13:57Z XXX followers, XXX engagements

"$OCUL HELIOS-2/3 for Diabetic Retinopathy will use same sites as SOL-R & SOL-1. Quick enrollment expected"
X Link @AscendingBio 2025-09-30T20:18Z XXX followers, XXX engagements

"$KURA $CAPR $MREO $RARE $DCTH LOOKING to Q4 Here are some companies to watch in Q4. They all are expecting significant results soon that are likely to move the stock price. I am anticipating good results from all of them. Yet there can always be a big surprise. Give these a look and see what you think of the potential risks and rewards. $KURA This is a company where they have such an active pipeline that it can be difficult to keep up with all the new developments. Yet I find that I am repeatedly pleased with their results. ESMO on Oct 17-21 is another opportunity for them to show strong"
X Link @AscendingBio 2025-09-30T13:48Z XXX followers, 1775 engagements

"$AQST Updated Corporate Presentation with AQST-108 Plan Phase 2a Study to begin soon with XX participants"
X Link @AscendingBio 2025-10-01T15:59Z XXX followers, 1792 engagements

"$OCUL Seeing Despite Being Blind On several occasions the $OCUL team has spoken about reviewing the blinded data. This is typically accompanied by an especially strong sense of confidence about the outcome. It appears they are able to go through the data and say "That participant looks like someone in the control group" and "That person has results that appear like what we would expect for the treatment group." When data like this seems to match the number of participants in each group that inspires confidence. For many studies blinded data offers few insights about the effectiveness of the"
X Link @AscendingBio 2025-10-08T15:28Z XXX followers, XXX engagements